Aksoy Elif, Oztutgan Turgut
Department of Pulmonology, Kolan International Hospital, Merkez, Kaptanpaşa Mahallesi Okmeydanı Kavşağı, Darülaceze Cd. No. 14, 34384 Okmeydanı Şişli, İstanbul, Turkey.
Case Rep Infect Dis. 2020 Aug 17;2020:8845844. doi: 10.1155/2020/8845844. eCollection 2020.
Currently, there are scarce data on how COVID-19 affects people with myasthenia gravis. Theoretically, there is a higher risk of experiencing severe manifestations of COVID-19 due to the common use of immunosuppressive drugs and potential respiratory failure in relation to respiratory muscle weakness. This is one of the early cases of COVID-19 reported in association with myasthenia gravis. Here, we highlight the prognosis, discuss the pathophysiological mechanisms, and prompt the consideration of convalescent plasma therapy in myasthenia gravis patients with concomitant COVID-19.
目前，关于新冠病毒病（COVID-19）如何影响重症肌无力患者的数据很少。从理论上讲，由于免疫抑制药物的普遍使用以及与呼吸肌无力相关的潜在呼吸衰竭，发生COVID-19严重表现的风险更高。这是报告的与重症肌无力相关的COVID-19早期病例之一。在此，我们强调预后，讨论病理生理机制，并促使考虑对合并COVID-19的重症肌无力患者采用恢复期血浆治疗。
